Chemours (NYSE:CC) Releases Earnings Results, Beats Estimates By $0.12 EPS

Key Points

• Chemours reported a quarterly earnings per share (EPS) of $0.58, exceeding analyst estimates by $0.12, while revenue rose by 5.0% compared to the same period last year.
• The company's stock price increased by 3.2%, reaching $12.60, with average trading volume of over 4 million shares.
• Chemours announced a dividend of $0.0875 per share, with a high payout ratio of 175.00%.

Chemours (NYSE:CC - Get Free Report) issued its quarterly earnings results on Tuesday. The specialty chemicals company reported $0.58 EPS for the quarter, topping analysts' consensus estimates of $0.46 by $0.12, Zacks reports. Chemours had a net margin of 0.54% and a return on equity of 23.82%. The company's revenue for the quarter was up 5.0% compared to the same quarter last year. During the same quarter last year, the firm earned $0.38 EPS. Chemours updated its Q3 2025 guidance to EPS and its FY 2025 guidance to EPS.

Chemours Stock Up 3.2%

Shares of NYSE:CC traded up $0.39 during midday trading on Tuesday, hitting $12.60. 4,218,210 shares of the company's stock were exchanged, compared to its average volume of 4,068,307. The company has a debt-to-equity ratio of 7.01, a current ratio of 1.75 and a quick ratio of 0.83. The stock has a 50 day moving average price of $12.10 and a 200-day moving average price of $13.41. The company has a market cap of $1.89 billion, a PE ratio of 63.00 and a beta of 1.61. Chemours has a 12 month low of $9.13 and a 12 month high of $22.38.

Chemours Dividend Announcement

The firm also recently announced a dividend, which was paid on Monday, June 16th. Stockholders of record on Monday, May 19th were given a dividend of $0.0875 per share. The ex-dividend date of this dividend was Friday, May 16th. This represents a dividend yield of 317.0%. Chemours's payout ratio is presently 175.00%.

Insider Activity

In other Chemours news, CFO Shane Hostetter bought 4,450 shares of the firm's stock in a transaction dated Monday, May 19th. The stock was bought at an average cost of $11.28 per share, with a total value of $50,196.00. Following the completion of the transaction, the chief financial officer directly owned 59,694 shares in the company, valued at approximately $673,348.32. The trade was a 8.06% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Damian Gumpel bought 7,822 shares of the firm's stock in a transaction dated Tuesday, June 3rd. The shares were acquired at an average cost of $9.95 per share, with a total value of $77,828.90. Following the completion of the transaction, the insider owned 131,701 shares of the company's stock, valued at $1,310,424.95. This represents a 6.31% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders have bought 25,672 shares of company stock valued at $251,573. 0.34% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Royal Bank of Canada boosted its holdings in Chemours by 6.8% during the first quarter. Royal Bank of Canada now owns 585,702 shares of the specialty chemicals company's stock worth $7,926,000 after purchasing an additional 37,382 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Chemours by 149.3% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,243 shares of the specialty chemicals company's stock valued at $593,000 after acquiring an additional 25,899 shares during the last quarter. Empowered Funds LLC purchased a new position in Chemours in the first quarter valued at about $403,000. AQR Capital Management LLC purchased a new position in Chemours in the first quarter valued at about $161,000. Finally, Baird Financial Group Inc. purchased a new position in Chemours in the first quarter valued at about $148,000. 76.26% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

CC has been the topic of a number of recent research reports. Royal Bank Of Canada lifted their price target on shares of Chemours from $14.00 to $15.00 and gave the stock an "outperform" rating in a report on Thursday, July 3rd. The Goldman Sachs Group lowered their target price on shares of Chemours from $21.00 to $14.00 and set a "neutral" rating for the company in a research note on Wednesday, May 14th. Truist Financial lowered their target price on shares of Chemours from $27.00 to $22.00 and set a "buy" rating for the company in a research note on Monday, April 14th. Barclays lowered their target price on shares of Chemours from $16.00 to $13.00 and set an "equal weight" rating for the company in a research note on Wednesday, May 28th. Finally, Morgan Stanley lowered their target price on shares of Chemours from $22.00 to $15.00 and set an "equal weight" rating for the company in a research note on Monday, May 12th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $17.44.

About Chemours

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.